Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652362 | 1.00 | LMNA (0.32) | LMNAGAAADAMTS5GCKHTT | |
| SCHEMBL4483442 | 0.81 | LMNA (0.32) | LMNAGAAHTT | |
| SCHEMBL2654965 | 0.81 | GCK (0.41) | ADAMTS5GCKHTT | |
| SCHEMBL2652742 | 0.80 | GCK (0.42) | GAAADAMTS5GCKHTT | |
| SCHEMBL2655888 | 0.77 | ADAMTS5 (0.42) | GAAADAMTS5GCKHTT | |
| SCHEMBL2652940 | 0.70 | SLC6A2 (0.41) | LMNAGCKHTT | |
| SCHEMBL2652562 | 0.69 | TDP1 (0.36) | LMNAGAAHTT | |
| SCHEMBL2654550 | 0.65 | POLB (0.43) | LMNAHTT | |
| SCHEMBL4480015 | 0.65 | LMNA (0.34) | LMNAGAAHTT | |
| SCHEMBL2654735 | 0.64 | GCK (0.44) | GCKHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | LMNA 4666/4885GAA 81/4885ADAMTS5 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.